Citations of work:

Allen E. Buchanan, Andrea Califano, Jeffrey Kahn, Elizabeth McPherson, John A. Robertson & Baruch A. Brody (2002). Pharmacogenetics: Ethical Issues and Policy Options.

9 found
Order:
Are we missing citations?

PhilPapers citations & references are currently in beta testing. We expect to add many more in the future.

Meanwhile, you can use our bibliography tool to import references for this or another work.

Or you can directly add citations for the above work:

Search for work by author name and title
Add directly by record ID

  1.  6
    Ethical Dimensions of Disparities in Depression Research and Treatment in the Pharmacogenomic Era.Lisa S. Parker & Valerie B. Satkoske - 2012 - Journal of Law, Medicine and Ethics 40 (4):886-903.
    Disparities in access to, and utilization of, treatment for depression among African-American and Caucasian elderly adults have been well-documented. Less fully explored are the multidimensional factors responsible for these disparities. The intersection of cultural constructs, socioeconomic factors, multiple levels of racism, and stigma attending both mental health issues and older age may help to explain disparities in the treatment of the depressed elderly. Personalized medicine with its promise of developing interventions tailored to an individual's health needs and genetically related response (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  2.  3
    Ethical Dimensions of Disparities in Depression Research and Treatment in the Pharmacogenomic Era.Lisa S. Parker & Valerie B. Satkoske - 2012 - Journal of Law, Medicine and Ethics 40 (4):886-903.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  3.  5
    A New Conceptual Gloss That Still Lacks Luster: Critiquing Morgan’s Treatment-Enhancement Distinction.John Gleaves - 2011 - Journal of the Philosophy of Sport 38 (1):103-112.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  4. Pharmacogenetics and Uncertainty: Implications for Policy Makers.Tom Ling & Ann Raven - 2006 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 37 (3):533-549.
    No categories
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  5.  24
    Pharmacogenetics and Uncertainty: Implications for Policy Makers.Tom Ling & Ann Raven - 2006 - Studies in History and Philosophy of Science Part C 37 (3):533-549.
    Uncertainty for policy makers is not new but the pressure to make decisions under conditions of uncertainty is perhaps greater than ever. The arrival of new scientific developments such as pharmacogenetics offers potentially great benefits . They have passionate supporters as well as doubters. The evidence is often extensive but unclear and policy makers may find themselves under pressure to make decisions before they feel that the evidence is compelling.The UK is particularly well placed to play a leading role in (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  6.  4
    Pharmacogenetic Testing, Informed Consent and the Problem of Secondary Information.Christian Netzer & Nikola Biller-Andorno - 2004 - Bioethics 18 (4):344–360.
  7.  14
    Ethical Implications of Pharmacogenetics – Do Slippery Slope Arguments Matter?Lilian Schubert - 2004 - Bioethics 18 (4):361–378.
  8.  1
    From the Guest Editor.Margit Sutrop - 2004 - Bioethics 18 (4):iii–viii.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  9.  40
    Tailor-Made Pharmacotherapy: Future Developments and Ethical Challenges in the Field of Pharmacogenomics.Johannes Van Delden, Ineke Bolt, Annemarie Kalis, Jeroen Derijks & Hubert Leufkens - 2004 - Bioethics 18 (4):303–321.
    In this article ethical issues are discussed which play a role in pharmacogenetics. Developments in pharmacogenetics have a large impact on many different practices such as clinical trials, the practice of medicine and society at large. In clinical trials, questions rise regarding the exclusion of genetic subgroups that may be non- or poor-responders to the experimental drug. Also, the question is asked how pharmaceutical companies should deal with their growing knowledge about the relations between genetic variation and adverse effects. Moreover, (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark